Virtual screening strategy was performed against the target β-tubulin to overcome paclitaxel resistance in blood cancer types. In essence, A185T and A248V are two such important mutations frequently observed in clinical trials that confer paclitaxel resistance. In the present investigation, compounds from NPACT database were filtered by pharmacokinetics, toxicity and binding energy values. A total of 5 active compounds were identified from a list of 1574 bioactive compounds investigated in our study. Finally, we have compiled all the characteristic features into biologically meaningful clusters by hierarchical clustering algorithm. Overall, the results from our analysis indicate that glaucarubol, isolated from the bark of Ailanthus excelsa tree, could be the potential lead molecule for the treatment of paclitaxel-resistant cancer types. It is worth stressing that our result is the first such observation of inhibitory action of glaucarubol against β-tubulin and warrants further experimental investigation. © 2017, Springer-Verlag.